首页 > 最新文献

JAMA ophthalmology最新文献

英文 中文
Challenges of Integrating Chatbot Use in Ophthalmology Diagnostics. 将聊天机器人应用于眼科诊断的挑战。
IF 7.8 1区 医学 Q1 OPHTHALMOLOGY Pub Date : 2024-09-01 DOI: 10.1001/jamaophthalmol.2024.2303
Shunsuke Koga, Wei Du
{"title":"Challenges of Integrating Chatbot Use in Ophthalmology Diagnostics.","authors":"Shunsuke Koga, Wei Du","doi":"10.1001/jamaophthalmol.2024.2303","DOIUrl":"10.1001/jamaophthalmol.2024.2303","url":null,"abstract":"","PeriodicalId":14518,"journal":{"name":"JAMA ophthalmology","volume":" ","pages":"883-884"},"PeriodicalIF":7.8,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141491953","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Challenges of Integrating Chatbot Use in Ophthalmology Diagnostics-Reply. 将聊天机器人应用于眼科诊断的挑战--回复。
IF 7.8 1区 医学 Q1 OPHTHALMOLOGY Pub Date : 2024-09-01 DOI: 10.1001/jamaophthalmol.2024.2306
Andrew Mihalache, Marko M Popovic, Rajeev H Muni
{"title":"Challenges of Integrating Chatbot Use in Ophthalmology Diagnostics-Reply.","authors":"Andrew Mihalache, Marko M Popovic, Rajeev H Muni","doi":"10.1001/jamaophthalmol.2024.2306","DOIUrl":"10.1001/jamaophthalmol.2024.2306","url":null,"abstract":"","PeriodicalId":14518,"journal":{"name":"JAMA ophthalmology","volume":" ","pages":"884"},"PeriodicalIF":7.8,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141491965","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Impact of Pediatric Instrument-Based Vision Screening. 基于仪器的儿科视力筛查的影响。
IF 7.8 1区 医学 Q1 OPHTHALMOLOGY Pub Date : 2024-09-01 DOI: 10.1001/jamaophthalmol.2024.2256
Isdin Oke, David G Hunter, Alison A Galbraith
{"title":"Impact of Pediatric Instrument-Based Vision Screening.","authors":"Isdin Oke, David G Hunter, Alison A Galbraith","doi":"10.1001/jamaophthalmol.2024.2256","DOIUrl":"10.1001/jamaophthalmol.2024.2256","url":null,"abstract":"","PeriodicalId":14518,"journal":{"name":"JAMA ophthalmology","volume":" ","pages":"882"},"PeriodicalIF":7.8,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141491969","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Biomarker Detection and Validation for Corneal Involvement in Patients With Acute Infectious Conjunctivitis. 急性传染性结膜炎患者角膜受累的生物标记检测与验证
IF 7.8 1区 医学 Q1 OPHTHALMOLOGY Pub Date : 2024-09-01 DOI: 10.1001/jamaophthalmol.2024.2891
Gerami D Seitzman, Lalitha Prajna, N Venkatesh Prajna, Wiwan Sansanayudh, Vannarut Satitpitakul, Wipada Laovirojjanakul, Cindi Chen, Lina Zhong, Kevin Ouimette, Travis Redd, Michael C Deiner, Travis C Porco, Stephen D McLeod, Thomas M Lietman, Armin Hinterwirth, Thuy Doan
<p><strong>Importance: </strong>Infectious conjunctivitis can lead to corneal involvement and result in ocular morbidity. The identification of biomarkers associated with corneal involvement has the potential to improve patient care.</p><p><strong>Objective: </strong>To identify biomarkers in patients with acute infectious conjunctivitis.</p><p><strong>Design, setting, and participants: </strong>This cross-sectional study took place from December 2016 to March 2024. Analyses were performed in 3 phases. First, logistic regression and machine learning algorithms were used to predict the probability of demonstrating corneal involvement in patients with presumed infectious conjunctivitis. Second, quantitative reverse transcription polymerase chain reaction (RT-qPCR) was used to confirm the most important biomarker gene identified by the algorithm. Third, the biomarker gene was validated in prospectively collected conjunctival samples of adult patients from 3 outpatient centers in Thailand and 1 in India. Patients with signs and symptoms of infectious conjunctivitis and onset within less than 14 days were eligible. Exclusion criteria were the inability to consent, presumed toxicity, or allergic conjunctivitis.</p><p><strong>Exposures: </strong>Acute infectious conjunctivitis.</p><p><strong>Main outcomes and measures: </strong>The identification and validation of ocular surface gene expression associated with corneal findings on slitlamp examination.</p><p><strong>Results: </strong>Thirteen genes exhibited a 1.5-log2 fold change in expression in patients with corneal involvement compared to patients without corneal involvement. Using the 13 genes to train and cross validate, logistic regression produced the highest mean area under the receiver operating characteristic curve (AUROC; 0.85; 95% CI, 0.84-0.86) for corneal involvement. The removal of apolipoprotein E (APOE) from the gene ensemble led to a decline in predictive performance of the logistic regression classifier (from mean AUROC 0.85 [95% CI, 0.84-0.86] to 0.74 [95% CI, 0.73-0.75]; adjusted P = .001 [Tukey test]). Orthogonal testing of APOE expression level with RT-qPCR showed that APOE expression was higher in patients with corneal involvement compared to patients without (median [IQR], 0.23 [0.04-0.47] vs 0.04 [0.02-0.06]; P = .004 [Mann-Whitney U test]). Using a Youden index of 0.23 Δ threshold cycle, APOE had a sensitivity of 56% (95% CI, 33-77) and a specificity of 88% (95% CI, 79-93) in 106 samples with conjunctivitis at Aravind, India (P < .001 [Fisher exact test]). When applied to a different patient population in Thailand, the same criteria could discriminate between disease states (58 samples; sensitivity, 47%; 95% CI, 30-64 and specificity, 93%; 95% CI, 77-99; P = .001 [Fisher exact test]).</p><p><strong>Conclusions and relevance: </strong>The results from this study suggest that the host conjunctival immune response can be meaningfully interrogated to identify biomarkers for ocular
重要性:感染性结膜炎可导致角膜受累,造成眼部疾病。确定与角膜受累相关的生物标志物有可能改善患者护理:鉴定急性传染性结膜炎患者的生物标志物:这项横断面研究于 2016 年 12 月至 2024 年 3 月进行。分析分三个阶段进行。首先,使用逻辑回归和机器学习算法预测推测感染性结膜炎患者出现角膜受累的概率。其次,使用定量反转录聚合酶链反应(RT-qPCR)确认算法确定的最重要的生物标记基因。第三,在泰国 3 个门诊中心和印度 1 个门诊中心收集的成年患者结膜样本中对生物标志基因进行了前瞻性验证。有感染性结膜炎症状和体征且发病时间少于 14 天的患者符合条件。排除标准为无法同意、假定中毒或过敏性结膜炎:急性传染性结膜炎:主要结果和测量方法:鉴定和验证与裂隙灯检查角膜结果相关的眼表基因表达:与无角膜受累的患者相比,13 个基因在角膜受累患者中的表达量出现了 1.5-log2 倍的变化。利用这 13 个基因进行训练和交叉验证,逻辑回归得出了角膜受累的最高平均接收器操作特征曲线下面积(AUROC;0.85;95% CI,0.84-0.86)。将脂蛋白 E(APOE)从基因组中剔除后,逻辑回归分类器的预测性能有所下降(从平均接收操作特征曲线下面积 0.85 [95% CI, 0.84-0.86] 降至 0.74 [95% CI, 0.73-0.75]; 调整后 P = .001 [Tukey 检验])。利用 RT-qPCR 对 APOE 表达水平进行的正交检验显示,角膜受累患者的 APOE 表达高于未受累患者(中位数 [IQR], 0.23 [0.04-0.47] vs 0.04 [0.02-0.06]; P = .004 [Mann-Whitney U 检验])。使用尤登指数 0.23 Δ临界周期,在印度 Aravind 的 106 份结膜炎样本中,APOE 的灵敏度为 56%(95% CI,33-77),特异性为 88%(95% CI,79-93)(P 结论和相关性:这项研究的结果表明,可以对宿主结膜免疫反应进行有意义的询问,以确定眼表疾病的生物标记物。
{"title":"Biomarker Detection and Validation for Corneal Involvement in Patients With Acute Infectious Conjunctivitis.","authors":"Gerami D Seitzman, Lalitha Prajna, N Venkatesh Prajna, Wiwan Sansanayudh, Vannarut Satitpitakul, Wipada Laovirojjanakul, Cindi Chen, Lina Zhong, Kevin Ouimette, Travis Redd, Michael C Deiner, Travis C Porco, Stephen D McLeod, Thomas M Lietman, Armin Hinterwirth, Thuy Doan","doi":"10.1001/jamaophthalmol.2024.2891","DOIUrl":"10.1001/jamaophthalmol.2024.2891","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Importance: &lt;/strong&gt;Infectious conjunctivitis can lead to corneal involvement and result in ocular morbidity. The identification of biomarkers associated with corneal involvement has the potential to improve patient care.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Objective: &lt;/strong&gt;To identify biomarkers in patients with acute infectious conjunctivitis.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Design, setting, and participants: &lt;/strong&gt;This cross-sectional study took place from December 2016 to March 2024. Analyses were performed in 3 phases. First, logistic regression and machine learning algorithms were used to predict the probability of demonstrating corneal involvement in patients with presumed infectious conjunctivitis. Second, quantitative reverse transcription polymerase chain reaction (RT-qPCR) was used to confirm the most important biomarker gene identified by the algorithm. Third, the biomarker gene was validated in prospectively collected conjunctival samples of adult patients from 3 outpatient centers in Thailand and 1 in India. Patients with signs and symptoms of infectious conjunctivitis and onset within less than 14 days were eligible. Exclusion criteria were the inability to consent, presumed toxicity, or allergic conjunctivitis.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Exposures: &lt;/strong&gt;Acute infectious conjunctivitis.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Main outcomes and measures: &lt;/strong&gt;The identification and validation of ocular surface gene expression associated with corneal findings on slitlamp examination.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;Thirteen genes exhibited a 1.5-log2 fold change in expression in patients with corneal involvement compared to patients without corneal involvement. Using the 13 genes to train and cross validate, logistic regression produced the highest mean area under the receiver operating characteristic curve (AUROC; 0.85; 95% CI, 0.84-0.86) for corneal involvement. The removal of apolipoprotein E (APOE) from the gene ensemble led to a decline in predictive performance of the logistic regression classifier (from mean AUROC 0.85 [95% CI, 0.84-0.86] to 0.74 [95% CI, 0.73-0.75]; adjusted P = .001 [Tukey test]). Orthogonal testing of APOE expression level with RT-qPCR showed that APOE expression was higher in patients with corneal involvement compared to patients without (median [IQR], 0.23 [0.04-0.47] vs 0.04 [0.02-0.06]; P = .004 [Mann-Whitney U test]). Using a Youden index of 0.23 Δ threshold cycle, APOE had a sensitivity of 56% (95% CI, 33-77) and a specificity of 88% (95% CI, 79-93) in 106 samples with conjunctivitis at Aravind, India (P &lt; .001 [Fisher exact test]). When applied to a different patient population in Thailand, the same criteria could discriminate between disease states (58 samples; sensitivity, 47%; 95% CI, 30-64 and specificity, 93%; 95% CI, 77-99; P = .001 [Fisher exact test]).&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusions and relevance: &lt;/strong&gt;The results from this study suggest that the host conjunctival immune response can be meaningfully interrogated to identify biomarkers for ocular","PeriodicalId":14518,"journal":{"name":"JAMA ophthalmology","volume":" ","pages":"865-871"},"PeriodicalIF":7.8,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11327903/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141982278","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Severe Spaceflight-Associated Neuro-Ocular Syndrome in an Astronaut With 2 Predisposing Factors. 一名宇航员的严重太空飞行相关神经-眼综合征有两个诱发因素。
IF 7.8 1区 医学 Q1 OPHTHALMOLOGY Pub Date : 2024-09-01 DOI: 10.1001/jamaophthalmol.2024.2385
Tyson J Brunstetter, Sara R Zwart, Keith Brandt, David M Brown, Simon J Clemett, Grace L Douglas, C Robert Gibson, Steven S Laurie, Andrew G Lee, Brandon R Macias, Thomas H Mader, Sara S Mason, Jessica U Meir, Andrew R Morgan, Mayra Nelman, Nimesh Patel, Clarence Sams, Rahul Suresh, William Tarver, Ann Tsung, Mary G Van Baalen, Scott M Smith

Importance: Understanding potential predisposing factors associated with spaceflight-associated neuro-ocular syndrome (SANS) may influence its management.

Objective: To describe a severe case of SANS associated with 2 potentially predisposing factors.

Design, setting, and participants: Ocular testing of and blood collections from a female astronaut were completed preflight, inflight, and postflight in the setting of the International Space Station (ISS).

Exposure: Weightlessness throughout an approximately 6-month ISS mission. Mean carbon dioxide (CO2) partial pressure decreased from 2.6 to 1.3 mm Hg weeks before the astronaut's flight day (FD) 154 optical coherence tomography (OCT) session. In response to SANS, 4 B-vitamin supplements (vitamin B6, 100 mg; L-methylfolate, 5 mg; vitamin B12, 1000 μg; and riboflavin, 400 mg) were deployed, unpacked on FD153, consumed daily through FD169, and then discontinued due to gastrointestinal discomfort.

Main outcomes and measures: Refraction, distance visual acuity (DVA), optic nerve, and macular assessment on OCT.

Results: Cycloplegic refraction was -1.00 diopter in both eyes preflight and +0.50 - 0.25 × 015 in the right eye and +1.00 diopter in the left eye 3 days postflight. Uncorrected DVA was 20/30 OU preflight, 20/16 or better by FD90, and 20/15 OU 3 days postflight. Inflight peripapillary total retinal thickness (TRT) peaked between FD84 and FD126 (right eye, 401 μm preflight, 613 μm on FD84; left eye, 404 μm preflight, 636 μm on FD126), then decreased. Peripapillary choroidal folds, quantified by surface roughness, peaked at 12.7 μm in the right eye on FD154 and 15.0 μm in the left eye on FD126, then decreased. Mean choroidal thickness increased throughout the mission. Genetic analyses revealed 2 minor alleles for MTRR 66 and 2 major alleles for SHMT1 1420 (ie, 4 of 4 SANS risk alleles). One-week postflight, lumbar puncture opening pressure was normal, at 19.4 cm H2O.

Conclusions and relevance: To the authors' knowledge, no other report of SANS documented as large of a change in peripapillary TRT or hyperopic shift during a mission as in this astronaut, and this was only 1 of 4 astronauts to experience chorioretinal folds approaching the fovea. This case showed substantial inflight improvement greater than the sensitivity of the measure, possibly associated with B-vitamin supplementation and/or reduction in cabin CO2. However, as a single report, such improvement could be coincidental to these interventions, warranting further evaluation.

重要性:了解与太空飞行相关神经眼综合征(SANS)有关的潜在易感因素可能会影响其管理:描述一例与两个潜在易感因素相关的严重 SANS 病例:对一名女宇航员进行了飞行前、飞行中和飞行后的眼部测试和采血,测试环境为国际空间站(ISS)。平均二氧化碳(CO2)分压在宇航员飞行日(FD)154 光学相干断层扫描(OCT)前几周从 2.6 mm Hg 降至 1.3 mm Hg。为应对 SANS,宇航员服用了 4 种 B 族维生素补充剂(维生素 B6,100 毫克;L-甲基叶酸,5 毫克;维生素 B12,1000 微克;核黄素,400 毫克),在 FD153 日拆封,每天服用直至 FD169 日,之后因胃肠道不适而停止服用:屈光度、远距离视力(DVA)、视神经和 OCT 黄斑评估:飞行前双眼屈光度均为-1.00屈光度,飞行 3 天后右眼屈光度为 +0.50 - 0.25 × 015,左眼屈光度为 +1.00屈光度。飞行前未校正 DVA 为 20/30 OU,飞行 90 天后为 20/16 或更好,飞行 3 天后为 20/15 OU。飞行中毛细血管周围视网膜总厚度(TRT)在 FD84 和 FD126 之间达到峰值(右眼,飞行前 401 μm,FD84 时 613 μm;左眼,飞行前 404 μm,FD126 时 636 μm),然后下降。用表面粗糙度量化的毛细血管周围脉络膜皱褶在 FD154 和 FD126 分别达到右眼 12.7 μm 和左眼 15.0 μm 的峰值,随后有所下降。在整个任务期间,平均脉络膜厚度都在增加。基因分析显示,MTRR 66有2个小等位基因,SHMT1 1420有2个大等位基因(即4个SANS风险等位基因中的4个)。飞行一周后,腰椎穿刺开口压力正常,为 19.4 cm H2O:据作者所知,没有其他关于 SANS 的报告像这名宇航员一样,在执行任务期间毛细血管周围 TRT 或远视偏移发生如此大的变化,而且这也是 4 名宇航员中仅有的一名出现接近眼窝的脉络膜视网膜皱褶的宇航员。该病例显示,飞行中视力的大幅改善超过了测量的灵敏度,这可能与补充 B 族维生素和/或减少舱内二氧化碳有关。然而,作为一份单一的报告,这种改善可能与这些干预措施巧合,值得进一步评估。
{"title":"Severe Spaceflight-Associated Neuro-Ocular Syndrome in an Astronaut With 2 Predisposing Factors.","authors":"Tyson J Brunstetter, Sara R Zwart, Keith Brandt, David M Brown, Simon J Clemett, Grace L Douglas, C Robert Gibson, Steven S Laurie, Andrew G Lee, Brandon R Macias, Thomas H Mader, Sara S Mason, Jessica U Meir, Andrew R Morgan, Mayra Nelman, Nimesh Patel, Clarence Sams, Rahul Suresh, William Tarver, Ann Tsung, Mary G Van Baalen, Scott M Smith","doi":"10.1001/jamaophthalmol.2024.2385","DOIUrl":"10.1001/jamaophthalmol.2024.2385","url":null,"abstract":"<p><strong>Importance: </strong>Understanding potential predisposing factors associated with spaceflight-associated neuro-ocular syndrome (SANS) may influence its management.</p><p><strong>Objective: </strong>To describe a severe case of SANS associated with 2 potentially predisposing factors.</p><p><strong>Design, setting, and participants: </strong>Ocular testing of and blood collections from a female astronaut were completed preflight, inflight, and postflight in the setting of the International Space Station (ISS).</p><p><strong>Exposure: </strong>Weightlessness throughout an approximately 6-month ISS mission. Mean carbon dioxide (CO2) partial pressure decreased from 2.6 to 1.3 mm Hg weeks before the astronaut's flight day (FD) 154 optical coherence tomography (OCT) session. In response to SANS, 4 B-vitamin supplements (vitamin B6, 100 mg; L-methylfolate, 5 mg; vitamin B12, 1000 μg; and riboflavin, 400 mg) were deployed, unpacked on FD153, consumed daily through FD169, and then discontinued due to gastrointestinal discomfort.</p><p><strong>Main outcomes and measures: </strong>Refraction, distance visual acuity (DVA), optic nerve, and macular assessment on OCT.</p><p><strong>Results: </strong>Cycloplegic refraction was -1.00 diopter in both eyes preflight and +0.50 - 0.25 × 015 in the right eye and +1.00 diopter in the left eye 3 days postflight. Uncorrected DVA was 20/30 OU preflight, 20/16 or better by FD90, and 20/15 OU 3 days postflight. Inflight peripapillary total retinal thickness (TRT) peaked between FD84 and FD126 (right eye, 401 μm preflight, 613 μm on FD84; left eye, 404 μm preflight, 636 μm on FD126), then decreased. Peripapillary choroidal folds, quantified by surface roughness, peaked at 12.7 μm in the right eye on FD154 and 15.0 μm in the left eye on FD126, then decreased. Mean choroidal thickness increased throughout the mission. Genetic analyses revealed 2 minor alleles for MTRR 66 and 2 major alleles for SHMT1 1420 (ie, 4 of 4 SANS risk alleles). One-week postflight, lumbar puncture opening pressure was normal, at 19.4 cm H2O.</p><p><strong>Conclusions and relevance: </strong>To the authors' knowledge, no other report of SANS documented as large of a change in peripapillary TRT or hyperopic shift during a mission as in this astronaut, and this was only 1 of 4 astronauts to experience chorioretinal folds approaching the fovea. This case showed substantial inflight improvement greater than the sensitivity of the measure, possibly associated with B-vitamin supplementation and/or reduction in cabin CO2. However, as a single report, such improvement could be coincidental to these interventions, warranting further evaluation.</p>","PeriodicalId":14518,"journal":{"name":"JAMA ophthalmology","volume":" ","pages":"808-817"},"PeriodicalIF":7.8,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11273286/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141758777","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Implications of Neighborhood- and Patient-Level Factors for Eye Care. 邻里和患者层面的因素对眼科护理的影响。
IF 7.8 1区 医学 Q1 OPHTHALMOLOGY Pub Date : 2024-09-01 DOI: 10.1001/jamaophthalmol.2024.3066
Patrice M Hicks, Maria A Woodward, Paula Anne Newman-Casey
{"title":"Implications of Neighborhood- and Patient-Level Factors for Eye Care.","authors":"Patrice M Hicks, Maria A Woodward, Paula Anne Newman-Casey","doi":"10.1001/jamaophthalmol.2024.3066","DOIUrl":"10.1001/jamaophthalmol.2024.3066","url":null,"abstract":"","PeriodicalId":14518,"journal":{"name":"JAMA ophthalmology","volume":" ","pages":"854-855"},"PeriodicalIF":7.8,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141901765","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Guttae Morphology After Cultured Corneal Endothelial Cell Transplant in Fuchs Endothelial Corneal Dystrophy. 培养角膜内皮细胞移植治疗富克斯内皮性角膜营养不良症后的角膜内皮形态。
IF 7.8 1区 医学 Q1 OPHTHALMOLOGY Pub Date : 2024-09-01 DOI: 10.1001/jamaophthalmol.2024.2718
Yasufumi Tomioka, Morio Ueno, Akihisa Yamamoto, Kohsaku Numa, Hiroshi Tanaka, Koji Kitazawa, Munetoyo Toda, Noriko Koizumi, Motomu Tanaka, Junji Hamuro, Chie Sotozono, Shigeru Kinoshita

Importance: Whether guttae in Fuchs endothelial corneal dystrophy (FECD) can be removed by polishing without Descemet stripping and whether postoperative maintenance of reduced guttae can be achieved through cultured corneal endothelial cell (CEC) transplant therapy are critical issues to be addressed.

Objective: To investigate the decrease of guttae through polishing degenerated CECs and abnormal extracellular matrix (ECM) without Descemet stripping and to observe the behavior of guttae following cultured CEC transplant.

Design, setting, and participants: This case series prospective observational study was conducted in a hospital outpatient clinic setting. Between December 2013 and January 2019, 22 eyes with corneal endothelial failure caused by FECD received cultured CEC transplant therapy at Kyoto Prefectural University Hospital. Of these, 15 eyes were consistently monitored at the same central corneal area during the preoperative phase, as well as in the early (within 1 year) and late (after 3 years) postoperative phases. The images from these phases were categorized into 3 groups: typical guttae, atypical guttae, and no guttae.

Exposures: Cultured CEC transplant therapy.

Main outcomes: Proportion of guttae in the observable area was measured, comparing the early and late postoperative phases for each group.

Results: The mean age of the patients at the time of surgery was 69 years (range, 49-79 years). All 15 eyes exhibited the presence of confluent guttae preoperatively (100%). Among these, 3 of 15 eyes belonged to male patients. The early postoperative phase of guttae morphologies was classified into 3 groups: 5 eyes with typical guttae, 7 with atypical guttae, and 3 with no guttae. The decrease in the number of these guttae was achieved by surgical procedures. The median percentage of guttae in the typical guttae, atypical guttae, and no guttae groups was 41.8%, 44.4%, and 16.2%, respectively, in the early phase, and 42.2%, 38.2%, and 18.8%, respectively, in the late phase.

Conclusions and relevance: The findings demonstrate that in some cases of FECD, guttae can be removed by scraping and polishing abnormal ECM and degenerated CECs, while preserving the Descemet membrane. Furthermore, cultured CEC transplant resulted in no increase in guttae for up to 3 years, providing insights into surgically eliminating guttae.

重要性:福氏内皮角膜营养不良症(Fuchs endothelial corne dystrophy,FECD)患者的角膜胶质是否可以通过抛光去除,而无需进行Descemet剥离,以及是否可以通过培养角膜内皮细胞(CEC)移植疗法实现术后维持减少的角膜胶质,这些都是亟待解决的关键问题:研究在不进行Descemet剥离的情况下,通过打磨变性的CEC和异常细胞外基质(ECM)来减少角膜基质,并观察培养的CEC移植后角膜基质的变化:本病例系列前瞻性观察研究在医院门诊进行。2013年12月至2019年1月期间,京都府立大学医院共收治了22例因FECD导致角膜内皮功能衰竭的患者。其中,15 只眼睛在术前阶段、术后早期(1 年内)和晚期(3 年后)在同一角膜中心区域接受了持续监测。这些阶段的图像被分为三组:典型角膜钙化、非典型角膜钙化和无角膜钙化:主要结果:主要结果:对各组术后早期和晚期进行比较,测量可观察区域的肠管比例:患者手术时的平均年龄为 69 岁(49-79 岁)。所有 15 只眼睛在术前都出现了融合性牙石(100%)。其中,男性患者占 15 眼中的 3 眼。术后早期的肠管形态分为三组:5 只眼睛有典型肠管,7 只眼睛有非典型肠管,3 只眼睛没有肠管。通过外科手术减少了这些钩突的数量。在早期阶段,典型钩突组、非典型钩突组和无钩突组的钩突百分比中位数分别为 41.8%、44.4% 和 16.2%,而在晚期阶段则分别为 42.2%、38.2% 和 18.8%:研究结果表明,在某些 FECD 病例中,可以通过刮除和抛光异常 ECM 和变性的 CEC 来去除胶质,同时保留 Descemet 膜。此外,培养的 CEC 移植后,在长达 3 年的时间里钩突没有增加,这为通过手术消除钩突提供了启示。
{"title":"Guttae Morphology After Cultured Corneal Endothelial Cell Transplant in Fuchs Endothelial Corneal Dystrophy.","authors":"Yasufumi Tomioka, Morio Ueno, Akihisa Yamamoto, Kohsaku Numa, Hiroshi Tanaka, Koji Kitazawa, Munetoyo Toda, Noriko Koizumi, Motomu Tanaka, Junji Hamuro, Chie Sotozono, Shigeru Kinoshita","doi":"10.1001/jamaophthalmol.2024.2718","DOIUrl":"10.1001/jamaophthalmol.2024.2718","url":null,"abstract":"<p><strong>Importance: </strong>Whether guttae in Fuchs endothelial corneal dystrophy (FECD) can be removed by polishing without Descemet stripping and whether postoperative maintenance of reduced guttae can be achieved through cultured corneal endothelial cell (CEC) transplant therapy are critical issues to be addressed.</p><p><strong>Objective: </strong>To investigate the decrease of guttae through polishing degenerated CECs and abnormal extracellular matrix (ECM) without Descemet stripping and to observe the behavior of guttae following cultured CEC transplant.</p><p><strong>Design, setting, and participants: </strong>This case series prospective observational study was conducted in a hospital outpatient clinic setting. Between December 2013 and January 2019, 22 eyes with corneal endothelial failure caused by FECD received cultured CEC transplant therapy at Kyoto Prefectural University Hospital. Of these, 15 eyes were consistently monitored at the same central corneal area during the preoperative phase, as well as in the early (within 1 year) and late (after 3 years) postoperative phases. The images from these phases were categorized into 3 groups: typical guttae, atypical guttae, and no guttae.</p><p><strong>Exposures: </strong>Cultured CEC transplant therapy.</p><p><strong>Main outcomes: </strong>Proportion of guttae in the observable area was measured, comparing the early and late postoperative phases for each group.</p><p><strong>Results: </strong>The mean age of the patients at the time of surgery was 69 years (range, 49-79 years). All 15 eyes exhibited the presence of confluent guttae preoperatively (100%). Among these, 3 of 15 eyes belonged to male patients. The early postoperative phase of guttae morphologies was classified into 3 groups: 5 eyes with typical guttae, 7 with atypical guttae, and 3 with no guttae. The decrease in the number of these guttae was achieved by surgical procedures. The median percentage of guttae in the typical guttae, atypical guttae, and no guttae groups was 41.8%, 44.4%, and 16.2%, respectively, in the early phase, and 42.2%, 38.2%, and 18.8%, respectively, in the late phase.</p><p><strong>Conclusions and relevance: </strong>The findings demonstrate that in some cases of FECD, guttae can be removed by scraping and polishing abnormal ECM and degenerated CECs, while preserving the Descemet membrane. Furthermore, cultured CEC transplant resulted in no increase in guttae for up to 3 years, providing insights into surgically eliminating guttae.</p>","PeriodicalId":14518,"journal":{"name":"JAMA ophthalmology","volume":" ","pages":"818-826"},"PeriodicalIF":7.8,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11413713/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141758776","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Filgotinib in Active Noninfectious Uveitis: The HUMBOLDT Randomized Clinical Trial. 菲格替尼治疗活动性非感染性葡萄膜炎:HUMBOLDT 随机临床试验。
IF 7.8 1区 医学 Q1 OPHTHALMOLOGY Pub Date : 2024-09-01 DOI: 10.1001/jamaophthalmol.2024.2439
Sunil K Srivastava, Timothy R Watkins, Quan Dong Nguyen, Sumit Sharma, David K Scales, Mark S Dacey, Rajiv E Shah, David S Chu, Dilraj S Grewal, Lisa J Faia, Eric B Suhler, Mark C Genovese, Ying Guo, William T Barchuk, Robin Besuyen, Andrew D Dick, James T Rosenbaum
<p><strong>Importance: </strong>Noninfectious uveitis is a leading cause of visual impairment with an unmet need for additional treatment options.</p><p><strong>Objective: </strong>To assess the efficacy and safety of filgotinib, a Janus kinase 1 (JAK1) preferential inhibitor, for the treatment of noninfectious uveitis.</p><p><strong>Design, setting, and participants: </strong>The HUMBOLDT trial was a double-masked, placebo-controlled, phase 2, randomized clinical trial conducted from July 2017 to April 2021 at 26 centers in 7 countries. Eligible participants (aged ≥18 years) had active noninfectious intermediate uveitis, posterior uveitis, or panuveitis despite at least 2 weeks of treatment with oral prednisone (10-60 mg per day).</p><p><strong>Interventions: </strong>Participants were randomly assigned 1:1 to receive filgotinib, 200 mg, or placebo orally once daily for up to 52 weeks.</p><p><strong>Main outcomes and measures: </strong>The primary end point was the proportion of participants experiencing treatment failure by week 24. Treatment failure was a composite end point represented by assessment of the presence of chorioretinal and/or retinal vascular lesions, best-corrected visual acuity, and anterior chamber cell and vitreous haze grades. Safety was assessed in participants who received at least 1 dose of study drug or placebo.</p><p><strong>Results: </strong>Between July 26, 2017, and April 22, 2021, 116 participants were screened, and 74 (mean [SD] age, 46 [16] years; 43 female [59.7%] of 72 participants, as 2 participants did not receive treatment doses) were randomly assigned to receive filgotinib (n = 38) or placebo (n = 36). Despite early termination of the trial for business reasons ahead of meeting enrollment targets, a significantly reduced proportion of participants who received filgotinib experienced treatment failure by week 24 vs placebo (12 of 32 participants [37.5%] vs 23 of 34 participants [67.6%]; difference vs placebo -30.1%; 95% CI, -56.2% to -4.1%; P = .006). Business reasons were unrelated to efficacy or safety. Adverse events were reported in 30 of 37 participants (81.1%) who received filgotinib and in 24 of 35 participants (68.6%) who received placebo. Serious adverse events were reported in 5 of 37 participants (13.5%) in the filgotinib group and in 2 of 35 participants (5.7%) in the placebo group. No deaths were reported during the trial.</p><p><strong>Conclusions and relevance: </strong>Results of this randomized clinical trial show that filgotinib lowered the risk of treatment failure in participants with active noninfectious intermediate uveitis, posterior uveitis, or panuveitis vs placebo. Although the HUMBOLDT trial provided evidence supporting the efficacy of filgotinib in patients with active noninfectious uveitis, the premature termination of the trial prevented collection of additional safety or efficacy information of this JAK1 preferential inhibitor.</p><p><strong>Trial registration: </strong>Clinical
重要性:非感染性葡萄膜炎是导致视力损伤的主要原因之一,对其他治疗方案的需求尚未得到满足:评估Janus激酶1(JAK1)优先抑制剂非戈替尼治疗非感染性葡萄膜炎的疗效和安全性:HUMBOLDT试验是一项双掩蔽、安慰剂对照的2期随机临床试验,于2017年7月至2021年4月在7个国家的26个中心进行。符合条件的参与者(年龄≥18岁)患有活动性非感染性中间葡萄膜炎、后葡萄膜炎或泛葡萄膜炎,尽管已接受至少2周的口服泼尼松(每天10-60毫克)治疗:参与者按1:1随机分配,接受菲戈替尼(200毫克)或安慰剂口服,每天一次,最长52周:主要终点是第24周时出现治疗失败的参与者比例。治疗失败是一个复合终点,由脉络膜和/或视网膜血管病变、最佳矫正视力以及前房细胞和玻璃体混浊等级的评估结果来表示。对至少接受过一次研究药物或安慰剂剂量的参与者进行了安全性评估:2017年7月26日至2021年4月22日期间,共筛选出116名参与者,并随机分配74名参与者(平均[标码]年龄为46[16]岁;72名参与者中有43名女性[59.7%],2名参与者未接受治疗剂量)接受非格替尼(n = 38)或安慰剂(n = 36)治疗。尽管在达到入组目标前因商业原因提前结束了试验,但与安慰剂相比,接受菲戈替尼治疗的参与者在第24周出现治疗失败的比例显著降低(32名参与者中有12名[37.5%]与34名参与者中有23名[67.6%]相比;与安慰剂相比,差异为-30.1%;95% CI,-56.2%至-4.1%;P = .006)。业务原因与疗效或安全性无关。接受非格替尼治疗的37名参与者中有30名(81.1%)报告了不良事件,接受安慰剂治疗的35名参与者中有24名(68.6%)报告了不良事件。菲戈替尼组37人中有5人(13.5%)出现严重不良事件,安慰剂组35人中有2人(5.7%)出现严重不良事件。试验期间无死亡报告:这项随机临床试验的结果表明,与安慰剂相比,菲戈替尼降低了活动性非感染性中间葡萄膜炎、后葡萄膜炎或泛葡萄膜炎患者治疗失败的风险。尽管HUMBOLDT试验为菲戈替尼在活动性非感染性葡萄膜炎患者中的疗效提供了证据支持,但试验的过早终止阻碍了收集这种JAK1优先抑制剂的更多安全性或疗效信息:试验注册:ClinicalTrials.gov Identifier:试验注册:ClinicalTrials.gov Identifier:NCT03207815。
{"title":"Filgotinib in Active Noninfectious Uveitis: The HUMBOLDT Randomized Clinical Trial.","authors":"Sunil K Srivastava, Timothy R Watkins, Quan Dong Nguyen, Sumit Sharma, David K Scales, Mark S Dacey, Rajiv E Shah, David S Chu, Dilraj S Grewal, Lisa J Faia, Eric B Suhler, Mark C Genovese, Ying Guo, William T Barchuk, Robin Besuyen, Andrew D Dick, James T Rosenbaum","doi":"10.1001/jamaophthalmol.2024.2439","DOIUrl":"10.1001/jamaophthalmol.2024.2439","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Importance: &lt;/strong&gt;Noninfectious uveitis is a leading cause of visual impairment with an unmet need for additional treatment options.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Objective: &lt;/strong&gt;To assess the efficacy and safety of filgotinib, a Janus kinase 1 (JAK1) preferential inhibitor, for the treatment of noninfectious uveitis.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Design, setting, and participants: &lt;/strong&gt;The HUMBOLDT trial was a double-masked, placebo-controlled, phase 2, randomized clinical trial conducted from July 2017 to April 2021 at 26 centers in 7 countries. Eligible participants (aged ≥18 years) had active noninfectious intermediate uveitis, posterior uveitis, or panuveitis despite at least 2 weeks of treatment with oral prednisone (10-60 mg per day).&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Interventions: &lt;/strong&gt;Participants were randomly assigned 1:1 to receive filgotinib, 200 mg, or placebo orally once daily for up to 52 weeks.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Main outcomes and measures: &lt;/strong&gt;The primary end point was the proportion of participants experiencing treatment failure by week 24. Treatment failure was a composite end point represented by assessment of the presence of chorioretinal and/or retinal vascular lesions, best-corrected visual acuity, and anterior chamber cell and vitreous haze grades. Safety was assessed in participants who received at least 1 dose of study drug or placebo.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;Between July 26, 2017, and April 22, 2021, 116 participants were screened, and 74 (mean [SD] age, 46 [16] years; 43 female [59.7%] of 72 participants, as 2 participants did not receive treatment doses) were randomly assigned to receive filgotinib (n = 38) or placebo (n = 36). Despite early termination of the trial for business reasons ahead of meeting enrollment targets, a significantly reduced proportion of participants who received filgotinib experienced treatment failure by week 24 vs placebo (12 of 32 participants [37.5%] vs 23 of 34 participants [67.6%]; difference vs placebo -30.1%; 95% CI, -56.2% to -4.1%; P = .006). Business reasons were unrelated to efficacy or safety. Adverse events were reported in 30 of 37 participants (81.1%) who received filgotinib and in 24 of 35 participants (68.6%) who received placebo. Serious adverse events were reported in 5 of 37 participants (13.5%) in the filgotinib group and in 2 of 35 participants (5.7%) in the placebo group. No deaths were reported during the trial.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusions and relevance: &lt;/strong&gt;Results of this randomized clinical trial show that filgotinib lowered the risk of treatment failure in participants with active noninfectious intermediate uveitis, posterior uveitis, or panuveitis vs placebo. Although the HUMBOLDT trial provided evidence supporting the efficacy of filgotinib in patients with active noninfectious uveitis, the premature termination of the trial prevented collection of additional safety or efficacy information of this JAK1 preferential inhibitor.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Trial registration: &lt;/strong&gt;Clinical","PeriodicalId":14518,"journal":{"name":"JAMA ophthalmology","volume":" ","pages":"789-797"},"PeriodicalIF":7.8,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11258638/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141633477","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Changes in Rates of Postprocedural Endophthalmitis and Treatments. 手术后眼内炎发病率和治疗方法的变化。
IF 7.8 1区 医学 Q1 OPHTHALMOLOGY Pub Date : 2024-09-01 DOI: 10.1001/jamaophthalmol.2024.2805
Seyyedehfatemeh Ghalibafan, Harry W Flynn, Nicolas A Yannuzzi
{"title":"Changes in Rates of Postprocedural Endophthalmitis and Treatments.","authors":"Seyyedehfatemeh Ghalibafan, Harry W Flynn, Nicolas A Yannuzzi","doi":"10.1001/jamaophthalmol.2024.2805","DOIUrl":"10.1001/jamaophthalmol.2024.2805","url":null,"abstract":"","PeriodicalId":14518,"journal":{"name":"JAMA ophthalmology","volume":" ","pages":"835-836"},"PeriodicalIF":7.8,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141859740","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Neighborhood-Level Social Determinants of Health and Presenting Characteristics for Rhegmatogenous Retinal Detachments. 邻里层面的健康社会决定因素与流变性视网膜脱离的表现特征。
IF 7.8 1区 医学 Q1 OPHTHALMOLOGY Pub Date : 2024-09-01 DOI: 10.1001/jamaophthalmol.2024.2889
Sally S Ong, Diep Tran, Erik Westlund, Ishrat Ahmed, Gregory B Russell, Anthony Gonzales, James T Handa, Cindy X Cai

Importance: Functional outcomes after repair of rhegmatogenous retinal detachments (RRDs) are highly dependent on baseline visual acuity and foveal status. Adverse social determinants of health (SDOH) can present barriers to timely presentation for repair and limit vision outcomes.

Objective: To evaluate the association between neighborhood-level SDOH with baseline severity (visual acuity and fovea status) of RRD.

Design, setting, and participants: This was a retrospective cohort study that included adult patients 18 years and older who underwent primary repair of uncomplicated RRD at the Wilmer Eye Institute from January 2008 to December 2018. Study data were analyzed from December 2023 to April 2024.

Exposures: The census block group of patient home addresses were matched to multiple neighborhood-level SDOH including the Area Deprivation Index (ADI), per capita income, percentage of renters, percentage of rent burden, percentage of people using a food assistance program, percentage of uninsured individuals, mode of transportation to work, distance to the nearest transit stop, total road density, National Walkability Index, Index of Medical Underservice score, and aggregate cost of medical care.

Main outcomes and measures: Odds of presenting with vision worse than 20/40 or fovea-involving RRD using multivariable logistic regression adjusting for age, sex, race and ethnicity, and insurance.

Results: A total of 700 patients (mean [SD] age, 57.9 [12.4] years; 432 male [61.7%]) were included. Every decile increase in ADI, indicating more socioeconomic disadvantage, was associated with an increased odds of presenting with worse visual acuity and fovea-involving RRD (odds ratio [OR], 1.14; 95% CI, 1.04-1.24; P = .004 and OR, 1.13; 95% CI, 1.04-1.22; P = .005, respectively). Each $1000 increase in per capita income was associated with lower odds of presenting with worse vision (OR, 0.99; 95% CI, 0.98-0.99; P = .001). Every 1% increase in percentage of workers who drove to work was associated with an increased odds of presenting with worse vision and fovea-involving RRD (OR, 1.02; 95% CI, 1.01-1.03; P = .005 and OR, 1.01; 95% CI, 1.00-1.03; P = .04, respectively).

Conclusions and relevance: Results of this cohort study suggest that patients with a residence in neighborhoods with more socioeconomic deprivation or a higher percentage of workers who drove to work were more likely to present with more severe RRD even after accounting for multiple individual-level characteristics. These findings support consideration of public policy changes to address the barriers faced by patients residing in certain neighborhoods who seek prompt surgical intervention for RRD to reduce health disparities in RRD outcomes.

重要性:流变性视网膜脱离(RRDs)修复后的功能效果在很大程度上取决于基线视力和眼窝状态。不利的社会健康决定因素(SDOH)会阻碍及时进行修复,并限制视力的恢复:评估邻里层面的 SDOH 与 RRD 基线严重程度(视力和眼窝状态)之间的关联:这是一项回顾性队列研究,纳入了2008年1月至2018年12月期间在威玛眼科研究所接受无并发症RRD初次修复的18岁及以上成年患者。研究数据分析时间为 2023 年 12 月至 2024 年 4 月:患者家庭住址的人口普查区组与多个邻里层面的 SDOH 相匹配,包括地区贫困指数(ADI)、人均收入、租房者比例、租房负担比例、使用食品援助计划者比例、无保险者比例、上班交通方式、到最近公交站点的距离、道路总密度、全国步行指数、医疗服务不足指数得分以及医疗总成本:采用多变量逻辑回归法,对年龄、性别、种族和民族以及保险进行调整,得出视力低于 20/40 或出现眼窝受累 RRD 的几率:共纳入 700 名患者(平均 [SD] 年龄,57.9 [12.4] 岁;432 名男性 [61.7%])。ADI 每增加十等分,表明社会经济条件更差,这与视力下降和眼窝受累 RRD 的发病几率增加有关(几率比 [OR],1.14;95% CI,1.04-1.24;P = .004 和 OR,1.13;95% CI,1.04-1.22;P = .005)。人均收入每增加 1000 美元,出现视力下降的几率就会降低(OR,0.99;95% CI,0.98-0.99;P = .001)。开车上班的工人比例每增加 1%,视力下降和眼窝受累 RRD 的几率就会增加(OR,1.02;95% CI,1.01-1.03;P = .005 和 OR,1.01;95% CI,1.00-1.03;P = .04):这项队列研究的结果表明,居住在社会经济贫困程度较高的社区或开车上班的工人比例较高的患者更有可能出现更严重的 RRD,即使考虑了多个个体层面的特征也是如此。这些研究结果支持考虑改变公共政策,以解决居住在某些社区的患者在寻求及时手术治疗 RRD 时所面临的障碍,从而减少 RRD 结果的健康差异。
{"title":"Neighborhood-Level Social Determinants of Health and Presenting Characteristics for Rhegmatogenous Retinal Detachments.","authors":"Sally S Ong, Diep Tran, Erik Westlund, Ishrat Ahmed, Gregory B Russell, Anthony Gonzales, James T Handa, Cindy X Cai","doi":"10.1001/jamaophthalmol.2024.2889","DOIUrl":"10.1001/jamaophthalmol.2024.2889","url":null,"abstract":"<p><strong>Importance: </strong>Functional outcomes after repair of rhegmatogenous retinal detachments (RRDs) are highly dependent on baseline visual acuity and foveal status. Adverse social determinants of health (SDOH) can present barriers to timely presentation for repair and limit vision outcomes.</p><p><strong>Objective: </strong>To evaluate the association between neighborhood-level SDOH with baseline severity (visual acuity and fovea status) of RRD.</p><p><strong>Design, setting, and participants: </strong>This was a retrospective cohort study that included adult patients 18 years and older who underwent primary repair of uncomplicated RRD at the Wilmer Eye Institute from January 2008 to December 2018. Study data were analyzed from December 2023 to April 2024.</p><p><strong>Exposures: </strong>The census block group of patient home addresses were matched to multiple neighborhood-level SDOH including the Area Deprivation Index (ADI), per capita income, percentage of renters, percentage of rent burden, percentage of people using a food assistance program, percentage of uninsured individuals, mode of transportation to work, distance to the nearest transit stop, total road density, National Walkability Index, Index of Medical Underservice score, and aggregate cost of medical care.</p><p><strong>Main outcomes and measures: </strong>Odds of presenting with vision worse than 20/40 or fovea-involving RRD using multivariable logistic regression adjusting for age, sex, race and ethnicity, and insurance.</p><p><strong>Results: </strong>A total of 700 patients (mean [SD] age, 57.9 [12.4] years; 432 male [61.7%]) were included. Every decile increase in ADI, indicating more socioeconomic disadvantage, was associated with an increased odds of presenting with worse visual acuity and fovea-involving RRD (odds ratio [OR], 1.14; 95% CI, 1.04-1.24; P = .004 and OR, 1.13; 95% CI, 1.04-1.22; P = .005, respectively). Each $1000 increase in per capita income was associated with lower odds of presenting with worse vision (OR, 0.99; 95% CI, 0.98-0.99; P = .001). Every 1% increase in percentage of workers who drove to work was associated with an increased odds of presenting with worse vision and fovea-involving RRD (OR, 1.02; 95% CI, 1.01-1.03; P = .005 and OR, 1.01; 95% CI, 1.00-1.03; P = .04, respectively).</p><p><strong>Conclusions and relevance: </strong>Results of this cohort study suggest that patients with a residence in neighborhoods with more socioeconomic deprivation or a higher percentage of workers who drove to work were more likely to present with more severe RRD even after accounting for multiple individual-level characteristics. These findings support consideration of public policy changes to address the barriers faced by patients residing in certain neighborhoods who seek prompt surgical intervention for RRD to reduce health disparities in RRD outcomes.</p>","PeriodicalId":14518,"journal":{"name":"JAMA ophthalmology","volume":" ","pages":"845-854"},"PeriodicalIF":7.8,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11310845/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141901738","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
JAMA ophthalmology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1